$2.6399
0.0399[1.53%]
Last update: 1:30PM Get Real Time Here
Nautilus Biotechnology
(NASDAQ:NAUT)Nautilus Biotechnology Stock (NASDAQ:NAUT), Analyst Ratings, Price Targets, Predictions
Nautilus Biotechnology Inc has a consensus price target of $4.8, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from Jefferies, Morgan Stanley, and Morgan Stanley on June 3, 2024, August 3, 2023, and August 3, 2022. With an average price target of $5 between Jefferies, Morgan Stanley, and Morgan Stanley, there's an implied 89.40% upside for Nautilus Biotechnology Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Morgan Stanley
Goldman Sachs
Cowen & Co.
Jefferies
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Nautilus Biotechnology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/03/2024 | Buy Now | 13.64% | Jefferies | Tycho Peterson | $5 → $3 | Assumes | Buy → Hold | Get Alert |
| 08/03/2023 | Buy Now | 127.28% | Morgan Stanley | Tejas Savant | $6 → $6 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/03/2022 | Buy Now | 127.28% | Morgan Stanley | Tejas Savant | $8 → $6 | Maintains | Equal-Weight | Get Alert |
| 08/03/2022 | Buy Now | -24.24% | Goldman Sachs | Matthew Sykes | $4 → $2 | Maintains | Neutral | Get Alert |
| 07/14/2022 | Buy Now | 51.52% | Goldman Sachs | Matthew Sykes | $5 → $4 | Maintains | Neutral | Get Alert |
| 04/13/2022 | Buy Now | 89.4% | Goldman Sachs | Matthew Sykes | $9 → $5 | Maintains | Neutral | Get Alert |
| 01/06/2022 | Buy Now | 203.04% | Morgan Stanley | Tejas Savant | → $8 | Initiates | → Equal-Weight | Get Alert |
| 11/02/2021 | Buy Now | — | Cowen & Co. | Max Masucci | — | Initiates | → Outperform | Get Alert |
| 08/04/2021 | Buy Now | 278.8% | Goldman Sachs | Matthew Sykes | — | Initiates | → Neutral | Get Alert |
| 07/13/2021 | Buy Now | 392.44% | Jefferies | Brandon Couillard | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Nautilus Biotechnology (NAUT)?
The latest price target for Nautilus Biotechnology (NASDAQ: NAUT) was reported by Jefferies on June 3, 2024. The analyst firm set a price target for $3.00 expecting NAUT to rise to within 12 months (a possible 13.64% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nautilus Biotechnology (NAUT)?
The latest analyst rating for Nautilus Biotechnology (NASDAQ: NAUT) was provided by Jefferies, and Nautilus Biotechnology their hold rating.
When was the last upgrade for Nautilus Biotechnology (NAUT)?
There is no last upgrade for Nautilus Biotechnology.
When was the last downgrade for Nautilus Biotechnology (NAUT)?
There is no last downgrade for Nautilus Biotechnology.
When is the next analyst rating going to be posted or updated for Nautilus Biotechnology (NAUT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.
Is the Analyst Rating Nautilus Biotechnology (NAUT) correct?
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a with a price target of $5.00 to $3.00. The current price Nautilus Biotechnology (NAUT) is trading at is $2.64, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.